{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T03:39:21Z","timestamp":1789184361058,"version":"build-2803163510"},"update-to":[{"DOI":"10.1002\/14651858.cd013020","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T00:00:00Z","timestamp":1606953600000}}],"reference-count":152,"publisher":"Wiley","issue":"12","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd013020.pub2","type":"journal-article","created":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T18:22:30Z","timestamp":1607019750000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis"],"prefix":"10.1002","volume":"2020","author":[{"given":"Tina","family":"Jakob","sequence":"additional","affiliation":[{"name":"Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonas Mehari","family":"Tesfamariam","sequence":"additional","affiliation":[{"name":"Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sascha","family":"Macherey","sequence":"additional","affiliation":[{"name":"University of Cologne; Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Cochrane Haematological Malignancies; Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Kuhr","sequence":"additional","affiliation":[{"name":"Institute of Medical Statistics and Computational Biology; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Adams","sequence":"additional","affiliation":[{"name":"Institute of Medical Statistics and Computational Biology; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ina","family":"Monsef","sequence":"additional","affiliation":[{"name":"Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Heidenreich","sequence":"additional","affiliation":[{"name":"Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Department of Urology; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Skoetz","sequence":"additional","affiliation":[{"name":"Cochrane Cancer, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,12,3]]},"reference":[{"key":"10.1002\/14651858.CD013020.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"4638","DOI":"10.1200\/jco.2006.24.18_suppl.4638","article-title":"Impact of zoledronic acid (Z) on pain in prostate cancer patients with bone metastases in a randomised placebo-control trial","volume":"24","author":"*Abetz","year":"2006","journal-title":"Journal of Clinical Oncology"},{"issue":"18","key":"10.1002\/14651858.CD013020.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"14544","DOI":"10.1200\/jco.2006.24.18_suppl.14544","article-title":"Effect of zoledronic acid (Z) on pain in prostate cancer patients with bone metastases based on performance status","volume":"24","author":"Barghout","year":"2006","journal-title":"Journal of Clinical Oncology - Supplement"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1200\/JCO.2013.51.6500","article-title":"Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance)","volume":"32","author":"*Smith","year":"2014","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1158\/1078-0432.CCR-06-0269","article-title":"Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer","volume":"12","author":"Cook","year":"2006","journal-title":"Clinical Cancer Research"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0005|cit5","first-page":"897","article-title":"CALGB 90202: a randomized double-blind, placebo-controlled phase III study of early vs standard zoledronic acid to prevent skeletal-related events in men with prostate cancer metastatic to the bone","volume":"4","author":"Smith","year":"2006","journal-title":"Clinical Advances in Hematology and Oncology"},{"issue":"2","key":"10.1002\/14651858.CD013020.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/BF02549644","article-title":"Effect of oral clodronate on bone pain: a controlled study in patients with metastatic prostate cancer","volume":"24","author":"*Elomaa","year":"1992","journal-title":"International Journal of Urology and Nephrology"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/0959-8049(94)90287-9","article-title":"The effect of clodronate on bone in metastatic prostate cancer. Histomorphometric report of a double-blind randomised placebo-controlled study","volume":"30","author":"Taube","year":"1994","journal-title":"European Journal of Cancer Part A: General Topics"},{"issue":"17","key":"10.1002\/14651858.CD013020.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1200\/JCO.2003.03.042","article-title":"Randomized, double-blind, controlled trial of mitoxantron\/prednisone and clodronate versus mitoxantrone\/prednisone and placebo in patients with hormone-refractory prostate cancer and pain","volume":"21","author":"*Ernst","year":"2003","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1097\/01.ju.0000147013.09157.8e","article-title":"A randomized, phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen independent prostate cancer and bone metastases","volume":"173","author":"*Figg","year":"2005","journal-title":"Journal of Urology"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1200\/JCO.2008.19.2146","article-title":"Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates","volume":"27","author":"*Fizazi","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0011|cit11","first-page":"viii153","article-title":"Denosumab in patients with bone metastases from castration-resistant prostate cancer and elevated bone resorption despite intravenous bisphosphonate (IV BP) therapy: analysis of a randomised phase II trial","volume":"19","author":"Fizazi","year":"2008","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.juro.2009.04.023","article-title":"Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial","volume":"182","author":"Fizazi","year":"2009","journal-title":"Journal of Urology"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.juro.2012.11.022","article-title":"Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial","volume":"189","author":"Fizazi","year":"2013","journal-title":"Journal of Urology"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"*Fizazi","year":"2011","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD013020.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/j.bone.2010.10.042","article-title":"Denosumab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer: results from a phase 3 randomized trial","volume":"48","author":"Brown","year":"2011","journal-title":"Bone"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"ix309","DOI":"10.1016\/S0923-7534(20)33497-9","article-title":"Denosumab in patients with metastatic prostate cancer previously treated with denosumab or zoledronic acid: 2-year open-label extension phase results from the pivotal phase 3 study","volume":"23","author":"Fizazi","year":"2012","journal-title":"Annals of Oncology"},{"issue":"18","key":"10.1002\/14651858.CD013020.pub2-BIB0017|cit17","first-page":"951","article-title":"A randomized phase III trial of denosumab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer [abstract no. LBA4507]","volume":"28","author":"Fizazi","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/jco.2012.30.15_suppl.4642","article-title":"Baseline covariates impacting overall survival (OS) in a phase III study of men with bone metastases from castration-resistant prostate cancer","volume":"30","author":"Fizazi","year":"2012","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0019|cit19","first-page":"11","article-title":"Denosumab and zoledronic acid (ZA) treatment in patients with genitourinary (GU) cancers and bone metastases","volume":"112","author":"Ganju","year":"2013","journal-title":"BJU International"},{"issue":"15","key":"10.1002\/14651858.CD013020.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"5075","DOI":"10.1200\/jco.2014.32.15_suppl.5075","article-title":"Symptomatic skeletal events (SSE) in patients with advanced prostate cancer: results from a phase III trial of denosumab for the prevention of skeletal-related events","volume":"32","author":"Klotz","year":"2014","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0021|cit21","first-page":"91","article-title":"2-year open-label extension phase results from the pivotal phase 3 study of denosumab in patients with metastatic castration resistant prostate cancer (CRPC) previously treated with denosumab or zoledronic acid","volume":"111","author":"Kueppers","year":"2013","journal-title":"BJU International"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0022|cit22","first-page":"24","article-title":"Denosumab or zoledronic acid therapy on pain interference and cancer-specific quality of life in patients with castrate-resistant prostate cancer and bone metastases","volume":"113","author":"Marx","year":"2014","journal-title":"BJU International"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"e262","DOI":"10.1016\/j.juro.2011.02.1550","article-title":"Benefit of denosumab therapy in patients with bone metastases from castrate resistant prostate cancer: a number-needed-to-treat (NNT) analysis","volume":"185","author":"Miller","year":"2011","journal-title":"Journal of Urology"},{"issue":"4","key":"10.1002\/14651858.CD013020.pub2-BIB0024|cit24","first-page":"e384","article-title":"Pain interference with daily functioning in patients with castrate-resistant prostate cancer: a comparison of denosumab and zoledronic acid","volume":"187","author":"Patrick","year":"2012","journal-title":"Journal of Urology"},{"issue":"4","key":"10.1002\/14651858.CD013020.pub2-BIB0025|cit25","first-page":"e286","article-title":"Effects of denosumab and zoledronic acid on pain interference with daily functioning in patients with castrate-resistant prostate cancer","volume":"185","author":"Patrick","year":"2011","journal-title":"Journal of Urology"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0026|cit26","first-page":"146","article-title":"A comparison of denosumab and zoledronic acid on pain interference with daily functioning in patients with castration-resistant prostate cancer","volume":"20","author":"Patrick","year":"2012","journal-title":"Supportive Care in Cancer"},{"issue":"4","key":"10.1002\/14651858.CD013020.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1200\/jco.2014.32.4_suppl.12","article-title":"Denosumab or zoledronic acid (ZA) therapy on pain interference and cancer-specific quality of life (CSQoL) in patients with castrate-resistant prostate cancer (CRPC) and bone metastases (BM)","volume":"32","author":"Patrick","year":"2014","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0028|cit28","first-page":"23","article-title":"Denosumab for the prevention of symptomatic skeletal events in patients with castration-resistant advanced prostate cancer: a comparison with skeletal-related events","volume":"113","author":"Pittman","year":"2014","journal-title":"BJU International"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"e933","DOI":"10.1016\/j.juro.2015.02.2686","article-title":"Bone turnover marker levels and outcomes in men with prostate cancer and bone metastases treated with bone antiresorptive agents","volume":"193","author":"Shore","year":"2015","journal-title":"Journal of Urology"},{"issue":"15","key":"10.1002\/14651858.CD013020.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"4533","DOI":"10.1200\/jco.2011.29.15_suppl.4533","article-title":"Effect of denosumab versus zoledronic acid in patients with castrate-resistant prostate cancer and bone metastases: subgroup analyses by prior SRE and baseline pain","volume":"29","author":"Shore","year":"2011","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD013020.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdu519","article-title":"Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events","volume":"26","author":"Smith","year":"2015","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1200\/jco.2014.32.4_suppl.35","article-title":"Denosumab for the prevention of symptomatic skeletal events in patients with castration-resistant advanced prostate cancer: a comparison with skeletal-related events","volume":"32","author":"Smith","year":"2014","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD013020.pub2-BIB0033|cit33","first-page":"139","article-title":"Acute-phase reactions: randomised, phase 3 study in patients with castrate resistant prostate cancer and bone metastases receiving zoledronic acid or denosumab","volume":"19","author":"Turner","year":"2011","journal-title":"Supportive Care in Cancer"},{"issue":"1","key":"10.1002\/14651858.CD013020.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.clgc.2013.07.002","article-title":"Failure to suppress markers of bone turnover on first-line hormone therapy for metastatic prostate cancer is associated with shorter time to skeletal-related event","volume":"12","author":"*Hahn","year":"2014","journal-title":"Clinical Genitourinary Cancer"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"4594","DOI":"10.1200\/jco.2011.29.15_suppl.4594","article-title":"Prognostic value of suppressed markers of bone turnover (BTO) after 6 months of androgen deprivation therapy (ADT) in prostate cancer","volume":"29","author":"Sharma","year":"2011","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"e15000","DOI":"10.1200\/jco.2010.28.15_suppl.e15000","article-title":"A randomized placebo-controlled trial of daily high-dose oral risedronate in men with metastatic prostate cancer commencing androgen deprivation therapy (ADT)","volume":"28","author":"Sweeney","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD013020.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0959-8049(05)80417-4","article-title":"Evaluation of the effect of oral clodronate on skeletal metastases with type I collagen metabolites. A controlled trial of the Finnish Prostate Cancer Group","volume":"29","author":"*Kylmala","year":"1993","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/bjc.1997.488","article-title":"Concomitant i.v. and oral clodronate in the relief of bone pain: a double-blind placebo-controlled study in patients with metastatic prostate cancer","volume":"76","author":"*Kylmala","year":"1997","journal-title":"British Journal of Cancer"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1016\/j.ejca.2012.05.014","article-title":"Randomised phase II\/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro)","volume":"48","author":"*Meulenbeld","year":"2012","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0040|cit40","doi-asserted-by":"crossref","unstructured":"*Michaelson MD Kaufman DS Kantoff P Oh WK Smith MR Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer Cancer 2012 107 3 530 5","DOI":"10.1002\/cncr.22043"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1007\/s11255-014-0824-9","article-title":"Docetaxel with or without zoledronic acid for castration-resistant prostate cancer","volume":"46","author":"*Pan","year":"2014","journal-title":"International Urology and Nephrology"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/S1470-2045(09)70201-3","article-title":"Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials","volume":"10","author":"*Dearnaley","year":"2009","journal-title":"Lancet Oncology"},{"issue":"17","key":"10.1002\/14651858.CD013020.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1093\/jnci\/djg038","article-title":"A double-blind, placebo-controlled, randomised trial of oral sodium clodronate for metastatic prostate cancer (MRC PRO5 Trial)","volume":"95","author":"Dearnaley","year":"2003","journal-title":"Journal of the National Cancer Institute"},{"issue":"9","key":"10.1002\/14651858.CD013020.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1200\/JCO.1995.13.9.2427","article-title":"Effect of oral clodronate on metastatic bone pain: a double-blind, placebo-controlled study","volume":"13","author":"*Robertson","year":"1995","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1464-410X.2007.06853.x","article-title":"Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid","volume":"100","author":"*Ryan","year":"2007","journal-title":"BJU International"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.urology.2010.05.026","article-title":"Zoledronic acid improves clinical outcomes when administered before onset of bone pain in patients with prostate cancer","volume":"76","author":"*Saad","year":"2010","journal-title":"Urology"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"390","DOI":"10.3816\/CGC.2007.n.022","article-title":"Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases","volume":"5","author":"Saad","year":"2007","journal-title":"Clinical Genitourinary Cancer"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","article-title":"Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer","volume":"96","author":"Saad","year":"2004","journal-title":"Journal of the National Cancer Institute"},{"issue":"19","key":"10.1002\/14651858.CD013020.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"e288","DOI":"10.1016\/j.juro.2011.02.1685","article-title":"Evaluation of prostate-specific antigen kinetics during zoledronic acid therapy for bone metastases in patients with castration-resistant prostate cancer","volume":"185","author":"Saad","year":"2011","journal-title":"Journal of Urology"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"e918","DOI":"10.1016\/S1569-9056(12)60915-4","article-title":"Prostate-specific antigen kinetics in patients with bone metastases from castration-resistant prostate cancer receiving zoledronic acid therapy","volume":"11","author":"Saad","year":"2012","journal-title":"European Urology, Supplements"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.eururo.2012.05.007","article-title":"Prostate-specific antigen kinetics and outcomes in patients with bone metastases from castration-resistant prostate cancer treated with or without zoledronic acid","volume":"65","author":"Saad","year":"2014","journal-title":"European Urology"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1093\/annonc\/mdl041","article-title":"Effect of zoledronic acid on pain associated with bone metastasis in patients with prostate cancer","volume":"17","author":"Weinfurt","year":"2006","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/annonc\/mdi122","article-title":"The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer","volume":"16","author":"Weinfurt","year":"2005","journal-title":"Annals of Oncology"},{"issue":"23","key":"10.1002\/14651858.CD013020.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1200\/JCO.2003.05.147","article-title":"Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostatic cancer","volume":"21","author":"*Small","year":"2003","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0022-5347(17)40597-0","article-title":"Palliation of painful bone metastases from prostate cancer using sodium etidronate: results of a randomized, prospective, double-blind, placebo-controlled study","volume":"141","author":"*Smith","year":"1989","journal-title":"Journal of Urology"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1200\/JCO.2016.69.0677","article-title":"Adding celecoxib with or without zoledronic acid for hormone-na\u00efve prostate cancer: long-term survival results from an adaptive, multiarm, multistage, platform, randomized controlled trial","volume":"35","author":"*Mason","year":"2017","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.clon.2008.07.002","article-title":"STAMPEDE: Systemic Therapy for Advancing or Metastatic Prostate Cancer\u2014A Multi-Arm Multi-Stage Randomised Controlled Trial","volume":"20","author":"James","year":"2008","journal-title":"Clinical Oncology"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1200\/jco.2012.30.5_suppl.26","article-title":"Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from STAMPEDE (MRC PR08, CRUK\/06\/019), a randomized controlled trial","volume":"30","author":"James","year":"2012","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1470-2045(12)70088-8","article-title":"Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial","volume":"13","author":"James","year":"2012","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"5001","DOI":"10.1200\/jco.2015.33.15_suppl.5001","article-title":"Docetaxel and\/or zoledronic acid for hormone-na\u00efve prostate cancer: first overall survival results from STAMPEDE (NCT00268476)","volume":"33","author":"James","year":"2015","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0063|cit63","first-page":"4717","article-title":"The analgesic efficacy of clodronate compared with placebo inpatients with painful bone metastases from prostatic cancer","volume":"17","author":"*Strang","year":"1997","journal-title":"Anticancer Research"},{"issue":"53","key":"10.1002\/14651858.CD013020.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta20530","article-title":"TRAPEZE: A randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer","volume":"20","author":"*James","year":"2016","journal-title":"Health Technology Assessment"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"e16108","DOI":"10.1200\/jco.2015.33.15_suppl.e16108","article-title":"Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer. (ISRCTN 12808747) TRAPEZE","volume":"33","author":"James","year":"2015","journal-title":"Journal of Clinical Oncology"},{"issue":"18","key":"10.1002\/14651858.CD013020.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"5000","DOI":"10.1200\/jco.2013.31.18_suppl.lba5000","article-title":"Clinical outcomes in patients with castrate-refractory prostate cancer (CRPC) metastatic to bone randomized in the factorial TRAPEZE trial to docetaxel (D) with strontium-89 (Sr89), zoledronic acid (ZA), neither, or both (ISRCTN 12808747)","volume":"31","author":"James","year":"2013","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1002\/14651858.CD013020.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1001\/jamaoncol.2015.5570","article-title":"Clinical outcomes and survival following treatment of metastatic castrate-refractory prostate cancer with docetaxel alone or with strontium-89, zoledronic acid, or both: the TRAPEZE randomized clinical trial","volume":"2","author":"James","year":"2016","journal-title":"JAMA Oncology"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"4677","DOI":"10.1200\/jco.2010.28.15_suppl.4677","article-title":"Initial feasibility and safety results from a phase II\/III clinical trial to evaluate docetaxel (D) therapy in combination with zoledronic acid (ZA) {+\/-} strontium-89 (Sr89) in hormone-refractory prostate cancer patients: ISRCTN12808747","volume":"28","author":"Porfiri","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s12032-013-0657-x","article-title":"Comparison between zoledronic acid and clodronate in the treatment of prostate cancer patients with bone metastases","volume":"30","author":"*Wang","year":"2013","journal-title":"Medical Oncology"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0070|cit70","first-page":"3837","article-title":"Efficacy of combined androgen blockade with zoledronic acid treatment in prostate cancer with bone metastasis: the ZABTON-PC (zoledronic acid\/androgen blockade trial on prostate cancer) study","volume":"33","author":"*Ueno","year":"2013","journal-title":"Anticancer Research"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s10147-016-1037-2","article-title":"A phase III multicenter, randomized, controlled study of combined androgen blockade with versus without zoledronic acid in prostate cancer patients with metastatic bone disease: results of the ZAPCA trial","volume":"22","author":"*Kamba","year":"2017","journal-title":"International Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1200\/jco.2015.33.7_suppl.150","article-title":"A phase III, multicenter, randomized, controlled study of maximum androgen blockade with versus without zoledronic acid in treatment-naive prostate cancer patients with bone metastases: results of ZAPCA study","volume":"33","author":"Kamba","year":"2015","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD013020.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1200\/JCO.2006.06.8197","article-title":"Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT investigators","volume":"25","author":"Beer","year":"2007","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD013020.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1359\/jbmr.090810","article-title":"Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure","volume":"25","author":"Body","year":"2010","journal-title":"Journal of Bone and Mineral Research"},{"issue":"1","key":"10.1002\/14651858.CD013020.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.bone.2010.10.048","article-title":"Incidence and outcomes of osteonecrosis of the jaw from an integrated analysis of three pivotal randomized double-blind, double-dummy phase 3 trials comparing denosumab and zoledronic acid for treatment of bone metastases in advanced cancer patients or myeloma","volume":"48","author":"Brown","year":"2011","journal-title":"Bone"},{"issue":"3","key":"10.1002\/14651858.CD013020.pub2-BIB0076|cit76","first-page":"195","article-title":"Denosumab is really effective in the treatment of osteoporosis secondary to hypogonadism in prostate carcinoma patients? A prospective randomized multicenter international study","volume":"13","author":"Doria","year":"2016","journal-title":"Clinical Cases in Mineral and Bone Metabolism"},{"issue":"3","key":"10.1002\/14651858.CD013020.pub2-BIB0077|cit77","first-page":"271","article-title":"Treatment of osteoporosis secondary to hypogonadism in prostate cancer patients: a prospective randomized multicenter international study with denosumab vs. alendronate","volume":"69","author":"Doria","year":"2017","journal-title":"Minerva Urologica e Nefrologica"},{"issue":"1","key":"10.1002\/14651858.CD013020.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1097\/00005392-200101000-00033","article-title":"The use of bisphosphonate for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer","volume":"165","author":"Heidenreich","year":"2001","journal-title":"Journal of Urology"},{"issue":"3","key":"10.1002\/14651858.CD013020.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/sj.pcan.4500574","article-title":"Ibandronate in the treatment of prostate cancer associated painful osseous metastases","volume":"5","author":"Heidenreich","year":"2002","journal-title":"Prostate Cancer and Prostatic Diseases"},{"issue":"15","key":"10.1002\/14651858.CD013020.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1200\/jco.2011.29.15_suppl.4643","article-title":"Randomized phase II trial evaluating different schedules of zoledronic acid administration on bone mineral density in patients with stage D prostate cancer beginning androgen deprivation","volume":"29","author":"Lang","year":"2011","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1002\/14651858.CD013020.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.clgc.2013.04.029","article-title":"A randomized phase ii trial evaluating different schedules of zoledronic acid on bone mineral density in patients with prostate cancer beginning androgen deprivation therapy","volume":"11","author":"Lang","year":"2013","journal-title":"Clinical Genitourinary Cancer"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0082|cit82","unstructured":"Radiotherapy with or without ibandronate in the treatment of painful bone metastases of prostate cancer trialregister.nl\/trial\/462"},{"issue":"1","key":"10.1002\/14651858.CD013020.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"e99","DOI":"10.1016\/S1569-9056(13)60591-6","article-title":"The impact of bone metastases on pain: results from a phase III denosumab study in men with nonmetastatic castration-resistant prostate cancer","volume":"12","author":"Patrick","year":"2013","journal-title":"European Urology, Supplements"},{"issue":"2","key":"10.1002\/14651858.CD013020.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0169-6009(90)90078-T","article-title":"Fast (4-h) or slow (24-h) infusions of pamidronate disodium (aminohydroxypropylidene diphosphonate (ADP)) as single shot treatment of hypercalcaemia","volume":"9","author":"Sawyer","year":"1990","journal-title":"Bone and Mineral"},{"issue":"6","key":"10.1002\/14651858.CD013020.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1016\/j.juro.2009.08.048","article-title":"Effects of Denosumab on Bone Mineral Density in Men Receiving Androgen Deprivation Therapy for Prostate Cancer","volume":"182","author":"Smith","year":"2009","journal-title":"Journal of Urology"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0086|cit86","unstructured":"Zoledronic acid in patients with metastatic prostate cancer treated with abiraterone acetate: impact on bone mineral density www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2013-001146-34"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0087|cit87","unstructured":"Effect of Zoledronic acid for Stage D2 hormone-sensitive prostate cancer patients upload.umin.ac.jp\/cgi-open-bin\/ctr_e\/ctr_view.cgi?recptno=R000003142"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0088|cit88","unstructured":"Randomized control study to evaluate the efficacy of Denosumab versus zoledronic acid for treatment of bone metastases in men with prostate cancer upload.umin.ac.jp\/cgi-open-bin\/ctr_e\/ctr_view.cgi?recptno=R000015153"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0089|cit89","unstructured":"Luteinizing hormone-releasing hormone analogue and enzalutamide +\/- zoledronic acid in prostate cancer patients clinicaltrials.gov\/show\/nct03336983"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0090|cit90","doi-asserted-by":"crossref","unstructured":"Alibhai S Zukotynski K Walker-Dilks C Emmenegger U Finelli A Morgan S Bone Health and Bone-Targeted Therapies for Prostate Cancer. A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO) Available from https:\/\/www.cancercareontario.ca\/en\/content\/bone-health-and-bone-targeted-therapies-prostate-cancer 2017","DOI":"10.7326\/M16-2577"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1055\/s-0029-1224109","article-title":"Efficacy and safety of denosumab in postmenopausal women with osteopenia or osteoporosis: a systematic review and a meta-analysis","volume":"41","author":"Anastasilakis","year":"2009","journal-title":"Hormone and Metabolic Research"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0092|cit92","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-540-69870-8","volume-title":"Bisphosphonates in Medical Practice\u2014Actions, Side Effects, Indications, Strategies","author":"Bartl","year":"2007"},{"issue":"6","key":"10.1002\/14651858.CD013020.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s00132-008-1280-y","article-title":"Use of bisphosphonates in orthopedic surgery","volume":"37","author":"Bartl","year":"2008","journal-title":"Der Orthop\u00e4de"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0094|cit94","unstructured":"Chaimani A Salanti G Becker L Caldwell D Higgins J Li T Protocol template for a Cochrane intervention review that compares multiple interventions methods.cochrane.org\/sites\/methods.cochrane.org.cmi\/files\/public\/uploads\/Protocol%20for%20Cochrane%20Reviews%20with%20Multiple%20Interventions.pdf"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jclinepi.2016.11.015","article-title":"Additional considerations are required when preparing a protocol for a systematic review with multiple interventions","volume":"83","author":"Chaimani","year":"2017","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/bonekey.2013.1","article-title":"Mechanisms of action of bisphosphonates in oncology: a scientific concept evolving from antiresorptive to anticancer activities","volume":"2","author":"Clezardin","year":"2013","journal-title":"BoneKEy Reports"},{"issue":"8 Suppl","key":"10.1002\/14651858.CD013020.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G","article-title":"Skeletal complications of malignancy","volume":"80","author":"Coleman","year":"1997","journal-title":"Cancer"},{"issue":"11","key":"10.1002\/14651858.CD013020.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/sj.bjc.6604382","article-title":"Risks and benefits of bisphosphonates","volume":"98","author":"Coleman","year":"2008","journal-title":"British Journal of Cancer"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0099|cit99","unstructured":"Deeks JJ Higgins JP Altman DG Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"7-8","key":"10.1002\/14651858.CD013020.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/sim.3767","article-title":"Checking consistency in mixed treatment comparison meta-analysis","volume":"29","author":"Dias","year":"2010","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/bonekey.2014.14","article-title":"Targeting RANKL in metastasis","volume":"3","author":"Dougall","year":"2014","journal-title":"BoneKEy Reports"},{"issue":"7109","key":"10.1002\/14651858.CD013020.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/j.ejca.2014.03.010","article-title":"Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel","volume":"50","author":"Fitzpatrick","year":"2014","journal-title":"European Journal of Cancer"},{"issue":"1","key":"10.1002\/14651858.CD013020.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa","year":"2006","journal-title":"Journal of Clinical Epidemiology"},{"issue":"2","key":"10.1002\/14651858.CD013020.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.eururo.2013.05.015","article-title":"Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-kB ligand inhibitors in patients with advanced prostate cancer","volume":"65","author":"Gartrell","year":"2014","journal-title":"European Urology"},{"issue":"5","key":"10.1002\/14651858.CD013020.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.eururo.2015.06.039","article-title":"Metastatic prostate cancer and the bone: significance and therapeutic options","volume":"68","author":"Gartrell","year":"2015","journal-title":"European Urology"},{"issue":"5","key":"10.1002\/14651858.CD013020.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.acuroe.2013.09.003","article-title":"Advances in prevention and treatment of bone metastases in prostate cancer. Role of RANK\/RANKL inhibition","volume":"37","author":"Gomez-Veiga","year":"2013","journal-title":"Actas Urologicals Espanolas"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0108|cit108","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime) 2015"},{"issue":"12","key":"10.1002\/14651858.CD013020.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1111\/ijcp.12022","article-title":"Denosumab: mechanism of action and clinical outcomes","volume":"66","author":"Hanley","year":"2012","journal-title":"International Journal of Clinical Practice"},{"issue":"3-4","key":"10.1002\/14651858.CD013020.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1177\/1756287216686018","article-title":"Denosumab treatment in the management of patients with advanced prostate cancer: clinical evidence and experience","volume":"9","author":"Hegemann","year":"2017","journal-title":"Therapeutic Advances in Urology"},{"issue":"11","key":"10.1002\/14651858.CD013020.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.14219\/jada.archive.2011.0108","article-title":"Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs","volume":"142","author":"Hellstein","year":"2011","journal-title":"Journal of the American Dental Association"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0112|cit112","unstructured":"Higgins JP Green S Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0113|cit113","unstructured":"Higgins JP Altman DG Sterne JA Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0114|cit114","unstructured":"Higgins JP Deeks JJ Altman DG Chapter 16: Special topics in statistics. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0115|cit115","unstructured":"Higgins JP Deeks JJ Chapter 7: Selecting studies and collecting data. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0116|cit116","unstructured":"Howlader N Noone AM Krapcho M Garshell J Neyman N Altekruse SF National Cancer Institute SEER Cancer Statistics Review, 1975-2010 www.seer.cancer.gov\/csr\/1975_2010"},{"issue":"11","key":"10.1002\/14651858.CD013020.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1002\/ijc.26024","article-title":"Steps in prostate cancer progression that lead to bone metastasis","volume":"128","author":"Jin","year":"2011","journal-title":"International Journal of Cancer"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1471-2288-13-35","article-title":"A graphical tool for locating inconsistency in network meta-analyses","volume":"13","author":"Krahn","year":"2013","journal-title":"BMC Medical Research Methodology"},{"issue":"2","key":"10.1002\/14651858.CD013020.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s00520-013-2017-y","article-title":"Use of bisphosphonates and the risk of osteonecrosis among cancer patients: a systemic review and meta-analysis of the observational studies","volume":"22","author":"Lee","year":"2014","journal-title":"Supportive Care in Cancer"},{"issue":"12","key":"10.1002\/14651858.CD013020.pub2-BIB0120|cit120","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006250.pub2","article-title":"Bisphosphonates for advanced prostate cancer","author":"Macherey","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"12","key":"10.1002\/14651858.CD013020.pub2-BIB0121|cit121","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003188.pub4","article-title":"Bisphosphonates in multiple myeloma: an updated network meta-analysis","author":"Mhaskar","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"10","key":"10.1002\/14651858.CD013020.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"62","author":"Moher","year":"2009","journal-title":"Journal of Clinical Epidemiology"},{"issue":"5","key":"10.1002\/14651858.CD013020.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"19","DOI":"10.6004\/jnccn.2019.0023","article-title":"Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology","volume":"17","author":"Mohler","year":"2019","journal-title":"Journal of the National Comprehensive Cancer Network"},{"issue":"4","key":"10.1002\/14651858.CD013020.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.eururo.2016.08.003","article-title":"EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: screening, diagnosis, and local treatment with curative intent","volume":"71","author":"Mottet","year":"2017","journal-title":"European Urology"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0125|cit125","unstructured":"Netmeta R\u00fccker G Schwarzer G Krahn U K\u00f6nig J CRAN.R-project.org\/package=netmeta 2017"},{"issue":"7","key":"10.1002\/14651858.CD013020.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.ejca.2010.02.041","article-title":"Bisphosphonates and RANK ligand inhibitors for the treatment and prevention of metastatic bone disease","volume":"46","author":"Neville-Webbe","year":"2010","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pmed.1003082","article-title":"CINeMA: An approach for assessing confidence in the results of a network meta-analysis","volume":"17","author":"Nikolakopoulou","year":"2020","journal-title":"PLOS Medicine"},{"issue":"10","key":"10.1002\/14651858.CD013020.pub2-BIB0128|cit128","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003474.pub4","article-title":"Bisphosphonates and other bone agents for breast cancer","author":"O'Carrigan","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD013020.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/sj.pcan.4500607","article-title":"The potential role of bisphosphonates in prostate cancer","volume":"5","author":"Oades","year":"2002","journal-title":"Prostate Cancer and Prostatic Diseases"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"v69","DOI":"10.1093\/annonc\/mdv222","article-title":"Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26 Suppl 5","author":"Parker","year":"2015","journal-title":"Annals of Oncology"},{"issue":"24","key":"10.1002\/14651858.CD013020.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0132|cit132","first-page":"g5630","article-title":"A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis","volume":"349","author":"Puhan","year":"2014","journal-title":"BMJ (Clinical research ed.)"},{"issue":"2","key":"10.1002\/14651858.CD013020.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10147-013-0561-6","article-title":"Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomised controlled trials","volume":"19","author":"Qi","year":"2014","journal-title":"International Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0134|cit134","unstructured":"R: A language and environment for statistical computing R Foundation for Statistical Computing 2017"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0135|cit135","first-page":"1261","article-title":"Bisphosphonates in the prevention and treatment of bone metastases","volume":"17","author":"Ramaswamy","year":"2003","journal-title":"Oncology"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0136|cit136","unstructured":"Review Manager 5 (RevMan 5) Nordic Cochrane Centre, The Cochrane Collaboration 2014"},{"issue":"1","key":"10.1002\/14651858.CD013020.pub2-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/jcb.25266","article-title":"Risks and benefits of bisphosphonate therapies","volume":"117","author":"Reyes","year":"2016","journal-title":"Journal of Cellular Biochemistry"},{"issue":"4","key":"10.1002\/14651858.CD013020.pub2-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/jrsm.1058","article-title":"Network meta-analysis, electrical networks and graph theory","volume":"3","author":"R\u00fccker","year":"2012","journal-title":"Research Synthesis Methods"},{"issue":"25","key":"10.1002\/14651858.CD013020.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.1002\/sim.6236","article-title":"Reduce dimension or reduce weights? Comparing two approaches to multi-arm studies in network meta-analysis","volume":"33","author":"R\u00fccker","year":"2014","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12874-015-0060-8","article-title":"Ranking treatments in frequentist network meta-analysis works without resampling methods","volume":"15","author":"R\u00fccker","year":"2015","journal-title":"BMC Medical Research Methodology"},{"issue":"7","key":"10.1002\/14651858.CD013020.pub2-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"e99682","DOI":"10.1371\/journal.pone.0099682","article-title":"Evaluating the quality of evidence from a network meta-analysis","volume":"9","author":"Salanti","year":"2014","journal-title":"PLOS ONE"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0142|cit142","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JPT Vist GE Glasziou P Guyatt GH Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0143|cit143","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JP Vist GE Glasziou P Guyatt GH Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0144|cit144","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-21416-0","volume-title":"Meta-Analysis With R","author":"Schwarzer","year":"2015"},{"issue":"8","key":"10.1002\/14651858.CD013020.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJMoa0809003","article-title":"Denosumab in men receiving androgen-deprivation therapy for prostate cancer","volume":"361","author":"Smith","year":"2009","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"240108","DOI":"10.1155\/2013\/240108","article-title":"Adverse effects of androgen deprivation therapy for prostate cancer: prevention and management","volume":"2013","author":"Sountoulides","year":"2013","journal-title":"ISRN Urology"},{"issue":"3","key":"10.1002\/14651858.CD013020.pub2-BIB0147|cit147","first-page":"65","article-title":"Osteoclast formation and differentiation: an overview","volume":"59","author":"Soysa","year":"2012","journal-title":"Journal of Medical and Dental Sciences"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0148|cit148","unstructured":"Sterne JAC Egger M Moher D Chapter 10: Addressing reporting biases. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematc Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.critrevonc.2019.02.004","article-title":"Adjuvant bisphosphonates or RANK-ligand inhibitors for patients with breast cancer and bone metastases: a systematic review and network meta-analysis","volume":"137","author":"Tesfamariam","year":"2019","journal-title":"Critical Reviews in Oncology\/Hematology"},{"issue":"1","key":"10.1002\/14651858.CD013020.pub2-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"478","DOI":"10.3390\/cancers3010478","article-title":"From prostate to bone: key players in prostate cancer bone metastasis","volume":"3","author":"Thobe","year":"2011","journal-title":"Cancers"},{"key":"10.1002\/14651858.CD013020.pub2-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"issue":"5","key":"10.1002\/14651858.CD013020.pub2-BIB0152|cit152","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013020","article-title":"Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a Cochrane Review and network meta-analysis","author":"Tesfamariam","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T02:35:16Z","timestamp":1710297316000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD013020.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Urology Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,12,3]]},"references-count":152,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,12]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd013020.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,3]]}}}